An interventional study of Placebo gel and Enamel Matrix Proteins Derivative in Mucositis and Peri Implant Mucositis, sponsored by University of Catania. Enrolling by invitation at 1 site in Italy. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-04.
Sponsored by University of Catania · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Mucositis with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Mucositis · Italy.
Among the 29 studies in Mucositis with a site in Italy, this one is the 10th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2024, is one of 19 with no phase, and was the 25th registered.
265 studies on the registry are indexed under Mucositis; 34 are open to participants now.
Browse Mucositis studies →3 of the 29 studies in Mucositis with a site in Italy are open now. Recruiting first, the newest first:
University of Pavia · Sites in Italy
Ages 18–70
Koite Health Oy · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 21 Mucositis studies recruiting now, 13 (62%) set no upper age limit and 7 (33%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 2 · Phase 4 1
First in 2006; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 54 is above the median of 45 across 215 interventional studies indexed under Mucositis.
Median enrollment 52 across the 23 interventional studies, 78 across the 6 observational. Of the 22 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 29 have an industry lead sponsor. The 10 most frequent:
University of Catania is the lead sponsor of 71 studies on the registry; 15 are open to participants now.
University of Catania has 3 studies filed under Mucositis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Mucositis with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the naturally occurring peri-implant mucositis (PM) treatment by means of non-surgical sub-marginal peri-implant instrumentation (NSPI) with or without use of enamel matrix protein derivative (EMD). Specifically, the primary outcome of the present study compared the efficacy of NSPI +EMD with respect to NSPI and placebo in the treatment of PM at 6 months follow-up by means of BOP reduction. The secondary outcome evaluated the influence of possible predictors on the BOP changes among all follow-up sessions.
Patients (n° 54) with Implants affected by PM were randomly assigned to test (NSMD+EMD) or control procedures (NSMD + placebo). At baseline, 1, 3, 6 months, full-mouth plaque score (FMPS), full-mouth bleeding score (FMBS), probing depth (PD), bleeding on probing (BOP), modified gingival index (mGI), and modified plaque index (mPlI) will assessed as well as levels of periodontal bacteria such as Aggregatibacter Actynomycencomitans, Porphyromonas Gingivalis, Tannerella Forsythia and Treponema Denticola. The BOP reduction was set as a primary outcome and the patient was considered statistical unit. Data were analysed to assess BOP reduction at a 6-month follow-up and to identify significant predictors of implant-site BOP through mixed generalized linear regression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients received a one-session of non-surgical sub-marginal peri-implant instrumentation (NSPI) with placebo
Other: Placebo gel
Patients received a one-session of non-surgical sub-marginal peri-implant instrumentation (NSPI) with EMD
Other: Enamel Matrix Proteins Derivative
Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of a placebo gel
Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of non-surgical treatment plus Enamel Matrix Proteins Derivative
Bleeding on probing (BOP) changes
The number of implants presenting with complete absence of BOP or implants with limited extent of BOP (≤1 spot/implant-the presence of a single spot)
Time frame: 6-months
Probing pocket depth (PPD) changes
Changes in PPD
Time frame: 6-months
Full mouth plaque score (FMPS) % changes
Full mouth plaque score (FMPS) % changes
Time frame: 6-months
Full mouth bleeding score (FMBS) % changes
Changes in FMBS
Time frame: 6-months
Plaque at implant sites according to modified gingival index (mGI) changes score
Changes in mGI 0-4 score
Time frame: 6-months
Plaque at implant sites according to modified plaque index (mPlI) changes score
Changes in mPlI 0-4 score
Time frame: 6-months
Patient-Reported Outcome Measures (PROMs)
Patient-Reported Outcome Measures (PROMs) Were evaluated PROMs such as the number of abscesses, systemic complications, gingival recession, excessive bleeding, allergic effects, systemic impacts and related drug side effects
Time frame: 6-months
Plan to share: Yes — Pubmed
Supporting information: Study protocol
Time frame: 6 months
Access criteria: pubmed databse
Data sharing details ↗ · pubmed.ncbi.nlm.nih.gov
No publications or documents are linked to this record.
Ran from Dec 2024 to primary completion in Feb 2025, 1 month.
Of 67 non-industry interventional studies with no phase under Mucositis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 26. This study's 1 month is below that.
Counting every sponsor, half of 70 studies reached it within 12 months; a quarter within 6 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Catania